Company Description
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer.
The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F.
Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | William Quinn |
Contact Details
Address: 900 Chesapeake Drive Redwood City, California 94063 United States | |
| Phone | 650 665 9295 |
| Website | boltbio.com |
Stock Details
| Ticker Symbol | BOLT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001641281 |
| CUSIP Number | 097702104 |
| ISIN Number | US0977021049 |
| Employer ID | 47-2804636 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William P. Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary and Director |
| Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer |
| Sarah Nemec | Vice President of Finance and Principal Accounting Officer |
| Wesley Burwell | Vice President and Head of Human Resources |
| Dr. Nathan Ihle Ph.D. | Senior Vice President of Pharmaceutical Operations |
| Dr. Dawn Colburn BCOP, Pharm.D. | Senior Vice President of Clinical Development |
| Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 4, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Jul 3, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| May 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2024 | 10-Q | Quarterly Report |